Abstract 3517
Background
The role of FDG-PET/CT in the FU of LA-HNSCC is unclear.
Methods
Scan reports of LA-HNSCC patients, having FU-FDG-PET/CT performed 6-18 months after ST/CRT were retrospectively analyzed. Equivocal reports were scored as positive. Excluded were patients with proven recurrence before FU-FDG-PET/CT. The reference standard was the occurrence of a second primary (SP) or a recurrence < 12 months after FU-FDG-PET/CT. Primary endpoints included sensitivity, specificity, positive (PPV) and negative predictive value (NPV) on a patient level.
Results
We identified 73 patients. Primary tumor site: oropharynx: n = 35; 7 larynx: n = 7; hypopharynx: n = 11; oral cavity: n = 4; paranasal sinus: n = 4; unknown: n = 5. Tumor stage (UICC 7): II (T2N0): n = 1; III: n = 9; IV: n = 63. T1: n = 8; T2: n = 20; T3: n = 16; T4: n = 24. N0: n = 10; N1: n = 7; N2: n = 53; N3: n = 2. Patients were treated by CRT (n = 29) or ST (n = 44). A prior FDG-PET/CT at 3 months after end of treatment (EOT) (EOT-FDG-PET/CT) had been performed in 69/73 (60 negative, 6 false and 3 true positive [resected lymph nodes]). FU-FDG-PET/CT in patients without EOT-FDG-PET/CT was true negative in 3 patients and true positive in 1. Median time between EOT and FU-FDG-PET/CT was 12 months (range 6-17). Median FU after FU-FDG-PET/CT was 48 months (range 2-130). Sensitivity, specificity, PPV and NPV were 83% (95% CI 52-98), 87% (95% CI 76-94), 56% (95% CI 31-78) and 96% (95% CI 87-100), respectively. Local recurrences, SP and distant metastases were detected in 5, 1, and 4 patients, respectively. One FU-FDG-PET/CT-detected local recurrence and 1 SP were treated with curative intent. All false-positive patients (n = 8) underwent biopsy (n = 3) or surgery (n = 5). 15 patients (21%) recurred > 12 months after FU-FDG-PET-CT. Median overall survival was 49 (95% CI 29 - 68) and 98 months (95% CI 86-111) in FU-FDG-PET/CT-positive and -negative patients, respectively (p = 0.000196).
Conclusions
FU-FDG-PET/CT in real-life has a high NPV and significant prognostic value. However, false-positive scans induce invasive procedures in a significant fraction of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract